F. Breitenbuecher

发表

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway

J. Melo, T. Brümmendorf, J. Duyster, 2010, Oncogene.

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade

J. Köhler, M. Schuler, K. Schmid, 2013, Oncogene.

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

R. Stone, S. Nimer, F. Giles, 2006, Blood.

LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells

R. Levine, S. Kasper, B. Markova, 2008, Molecular Cancer Therapeutics.

Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy

T. Gauler, M. Schuler, K. Schmid, 2014, Cell Death and Disease.

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C

H. Gschaidmeier, S. Kasper, F. Breitenbuecher, 2003, Leukemia.

Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.

A. Marx, H. Gschaidmeier, C. Peschel, 2004, Blood.

inhibitors in AML A novel molecular mechanism of primary resistance to FLT3-kinase

Kristina Masson, S. Kasper, B. Markova, 2014 .

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

Kristina Masson, L. Rönnstrand, S. Kasper, 2009, Blood.

A Novel Molecular Mechanism of Primary Resistance to FLT 3-Kinase Inhibitors in Acute Myeloid Leukemia

Kristina Masson, L. Rönnstrand, S. Kasper, 2009 .

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

E. Estey, Chunaram Choudhary, A. Gratwohl, 2005, Blood.

Plasma sequencing to detect a multitude of secondary KIT resistance mutations in metastatic gastrointestinal stromal tumors (GIST).

M. Schuler, T. Herold, F. Breitenbuecher, 2015 .

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.

T. Haferlach, S. Schnittger, J. Duyster, 2009, Blood.

Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers.

M. Skwarczynska, C. Ottmann, M. Schuler, 2013, ACS chemical biology.

Inactivation of Capicua drives cancer metastasis

S. Asthana, Matan Hofree, V. Miller, 2016, Nature Genetics.

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

K. Döhner, R. Schlenk, H. Döhner, 2009, Blood.

Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer

M. Schuler, S. Kasper, B. Markova, 2012, Journal of Cancer Research and Clinical Oncology.

The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.

S. Kasper, B. Markova, F. Breitenbuecher, 2008, Leukemia research.

Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer

M. Schuler, G. Iliakis, F. Breitenbuecher, 2017, Journal of Cancer Research and Clinical Oncology.

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy

M. Schuler, K. Schmid, K. Worm, 2017, Oncotarget.

DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.

J. Fletcher, M. Schuler, F. Grabellus, 2013, Cancer research.

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies

M. Schuler, S. Kasper, B. Markova, 2012, Blood Cancer Journal.

Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer

M. Schuler, F. Breitenbuecher, M. Guyot, 2012, Journal of Cancer Research and Clinical Oncology.

Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients

L. Freitag, J. Köhler, T. Gauler, 2014, PloS one.

Cross-inhibition of interferon-induced signals by GM-CSF through a block in Stat1 activation.

S. Kasper, F. Breitenbuecher, C. Huber, 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536

J. von Pawel, M. Werner, C. Kortsik, 2017, Oncology Research and Treatment.

MITF is a critical regulator of the carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) in malignant melanoma

D. Schadendorf, I. Helfrich, F. Breitenbuecher, 2015, Pigment cell & melanoma research.

Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity

M. Schuler, S. Kasper, F. Breitenbuecher, 2014, Cell Death and Disease.

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

A. Marx, H. Gschaidmeier, F. Breitenbuecher, 2003, Blood.

The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells.

R. Levine, S. Kasper, B. Markova, 2007 .

Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients

Martin Eisenacher, Maike Ahrens, Stefan Welter, 2016, Journal of Cancer Research and Clinical Oncology.

Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung Cancer

M. Schuler, B. Markova, F. Breitenbuecher, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Therapeutics , Targets , and Chemical Biology DOG 1 Regulates Growth and IGFBP 5 in Gastrointestinal Stromal Tumors

J. Fletcher, M. Schuler, F. Grabellus, 2013 .

Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS‐TBNA Specimens From Patients With Lung Adenocarcinoma

K. Darwiche, L. Freitag, M. Schuler, 2018, Clinical lung cancer.

A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer

N. Reinmuth, Michael Thomas, M. Schuler, 2021, Therapeutic advances in medical oncology.